Myeloma, MGUS and related conditions: A Guide for GPs
This guide is written for GPs to help in the diagnosis of myeloma and monoclonal gammopathies. Primary care clinicians play a critical role in the early diagnosis of myeloma
This guide is written for GPs to help in the diagnosis of myeloma and monoclonal gammopathies. Primary care clinicians play a critical role in the early diagnosis of myeloma
In collaboration with BMJ Learning, we have created a new course for GPs on myeloma. This interactive course gives practical tips on the detection and diagnosis of myeloma and MGUS.
We have partnered with GatewayC on their updated Myeloma Early Diagnosis course, available for all primary care professionals.
This course aims to increase GPs’ awareness of patients with suspected myeloma and support them to undertake the appropriate investigations and understand how to interpret the results.
The Clinical Trials Research Unit at the University of Leeds has produced a series of webinars for researchers and clinicians about the UK Myeloma Research Alliance (UKMRA)-Myeloma UK-Concept and Access Research Programme (CARP) and how it supports the development of early phase myeloma clinical trials in the UK.
Please click the image to view the tool. Early diagnosis of myeloma relies on primary care clinicians being able to accurately suspect, test and refer patients with suspected myeloma. It is important that GPs are able to distinguish those patients that require urgent investigation in secondary care versus those that likely have lower risk MGUS and so can…
The haematological malignancies patient report outcomes (HM-PRO) measure has been developed to support patients and their clinicians in discussing, addressing and better recording quality of life issues that matter patients.
Access the questionnaire here.
Common Terminology Criteria for Adverse Events (CTCAE) is widely accepted as the standard classification and severity grading scale for adverse events in cancer therapy, clinical trials and other oncology settings. Version 5.0 is the most updated document (November 27, 2017)
Bortezomib is recommended as induction treatment in combination with dexamethasone, or with dexamethasone and thalidomide, for previously untreated myeloma patients who are eligible for high-dose chemotherapy and haematopoietic stem cell transplantation.